Nature Medicine
Novartis Pharmaceuticals asked for an image to accompany their cover story for Volume 28 Issue 2 of of the highly acclaimed
Nature Medicine
Novartis Pharmaceuticals asked for an image to accompany their cover story for Volume 28 Issue 2 of of the highly acclaimed
Nature Medicine
Fowler et. al report their primary analysis of the ELARA phase 2 trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, that showed a robust response and manageable safety profile in heavily pre-treated patients with relapsed/refractory follicular lymphoma. Captured in a moment of suspense, the illustrated cover casts a retro space-age mood over the scene as a tisagenlecleucel CAR T cell recognizes and targets a CD19-expressing follicular lymphoma within the tumor microenvironment, highlighting the selective and specific mechanism of this novel cellular therapy.
Fowler et. al report their primary analysis of the ELARA phase 2 trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, that showed a robust response and manageable safety profile in heavily pre-treated patients with relapsed/refractory follicular lymphoma. Captured in a moment of suspense, the illustrated cover casts a retro space-age mood over the scene as a tisagenlecleucel CAR T cell recognizes and targets a CD19-expressing follicular lymphoma within the tumor microenvironment, highlighting the selective and specific mechanism of this novel cellular therapy.
R E F E R E N C E S
R E F E R E N C E S
R E F E R E N C E S
R E F E R E N C E S
Fowler, N.H., Dickinson, M., Dreyling, M. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28, 325–332 (2022). https://doi.org/10.1038/s41591-021-01622-0
Fowler, N.H., Dickinson, M., Dreyling, M. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28, 325–332 (2022). https://doi.org/10.1038/s41591-021-01622-0
Fowler, N.H., Dickinson, M., Dreyling, M. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28, 325–332 (2022). https://doi.org/10.1038/s41591-021-01622-0